Which of the following is incorrect about anidulafungin?
A. Dosage adjustments are not required for renal and hepatic impairment, and there is no known clinically relevant drug-drug interaction .
B. Dosage reduction is required for geriatric patients
C. It is indicated in candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), but it has has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida, and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in this group.
D. In the treatment of esophageal candidiasis, it showed higher endoscopic relapse rates at follow-up at 2 weeks post-treatment, compared with fluconazole.


Answer: B
Dosage adjustment is not required for geriatric patients.


References
1. Eraxis prescribing information
2. 2009 May - Grand Round: Echinocandin in the ICU – A clinical and pharmacoeconomics advance